{"id":"mci-186-in-open-label-phase","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"}]},"_chembl":null,"_fixedAt":"2026-03-30T17:16:37.282887","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"MCI-186 works by neutralizing free radicals, which are unstable molecules that can cause oxidative stress and damage to cells. This can help to reduce inflammation and protect against cell death.","oneSentence":"MCI-186 is a free radical scavenger.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:25.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ischemic stroke"}]},"_fixedFields":["modality→Biologic"],"trialDetails":[{"nctId":"NCT04776135","phase":"PHASE1","title":"Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2021-02-26","conditions":"Healthy Adult Subjects","enrollment":36},{"nctId":"NCT01492686","phase":"PHASE3","title":"Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-12","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":137},{"nctId":"NCT04577404","phase":"PHASE3","title":"Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2020-10-29","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":124},{"nctId":"NCT04370431","phase":"PHASE1","title":"A Study of TTYP01 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2020-04-24","conditions":"Healthy Adult Subjects","enrollment":72},{"nctId":"NCT06107205","phase":"PHASE1","title":"Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2023-11-07","conditions":"Healthy Adult Subjects","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MCI-186 in open label phase","genericName":"MCI-186 in open label phase","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MCI-186 is a free radical scavenger. Used for Ischemic stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}